Advertisement

Annals of Surgical Oncology

, Volume 25, Supplement 3, pp 850–851 | Cite as

ASO Author Reflections: RAS Mutations in Metastatic Colorectal Cancer

  • Guillaume Passot
  • Jean-Nicolas Vauthey
  • Yun Shin ChunEmail author
ASO Author Reflections
  • 51 Downloads

Notes

DISCLOSURES

Guillaume Passot, Jean-Nicolas Vauthey, and Yun Shin Chun have no conflicts of interest to disclose.

References

  1. 1.
    Vauthey JN, Zimmitti G, Kopetz SE et al. RAS mutation status predicts survival and patterns of recurrence in patients undergoing hepatectomy for colorectal liver metastases. Ann Surg. 2013;258(4):619–26; discussion 626–617.CrossRefGoogle Scholar
  2. 2.
    Brudvik KW, Kopetz SE, Li L, Conrad C, Aloia TA, Vauthey JN. Meta-analysis of KRAS mutations and survival after resection of colorectal liver metastases. Br J Surg. 2015;102(10):1175–83.CrossRefGoogle Scholar
  3. 3.
    Yamashita S, Chun YS, Kopetz SE, Vauthey JN. Biomarkers in colorectal liver metastases. Br J Surg. 2018;105(6):618–27.CrossRefGoogle Scholar
  4. 4.
    Passot G, Kim BJ, Glehen O et al. Impact of RAS mutations in metastatic colorectal cancer after potentially curative resection: does site of metastases matter? Ann Surg Oncol. 2018;25(1):179–87.CrossRefGoogle Scholar
  5. 5.
    Chun YS, Passot G, Yamashita S et al. Deleterious effect of RAS and evolutionary high-risk TP53 double mutation in colorectal liver metastases. Ann Surg.  https://doi.org/10.1097/sla.0000000000002450.

Copyright information

© Society of Surgical Oncology 2018

Authors and Affiliations

  • Guillaume Passot
    • 1
    • 2
  • Jean-Nicolas Vauthey
    • 1
  • Yun Shin Chun
    • 1
    Email author
  1. 1.Department of Surgical OncologyThe University of Texas MD Anderson Cancer CenterHoustonUSA
  2. 2.Department of Surgical Oncology, Hospices Civils de Lyon, CH Lyon SudEMR 37-38 University Lyon 1LyonFrance

Personalised recommendations